Biologic targeting in the treatment of inflammatory bowel diseases.
The etiology of inflammatory bowel disease (IBD) has not yet been clarified and immunosuppressive agents which nonspecifically reduce inflammation and immunity have been used in the conventional therapies for IBD. Evidence indicates that a dysregulation of mucosal immunity in the gut of IBD causes an overproduction of inflammatory cytokines and trafficking of effector leukocytes into the bowel, thus leading to an uncontrolled intestinal inflammation. Under normal situations, the intestinal mucosa is in a state of "controlled" inflammation regulated by a delicate balance of proinflammatory (tumor necrosis factor [TNF-alpha], interferon-gamma [IFN-gamma], interleukin-1 [IL-1], IL-6, IL-12 and anti-inflammatory cytokines IL-4, IL-10, IL-11). The mucosal immune system is the central effector of intestinal inflammation and injury, with cytokines playing a central role in modulating inflammation. Cytokines may therefore be a logical target for inflammatory bowel disease therapy using specific cytokine inhibitors. Biotechnology agents targeted against TNF, leukocyte adhesion, Th1 polarization, T cell activation, nuclear factor-kappaB (NF-kappaB), and other miscellaneous therapies are being evaluated as potential therapies for the treatment of inflammatory bowel disease. In this context, infliximab and adalimumab are currently the only biologic agents approved in Europe for the treatment of inflammatory Crohn's disease. Other anti-TNF biologic agents have emerged, including CDP571, certolizumab pegol, etanercept, onercept. However, ongoing research continues to generate new biologic agents targeted at specific pathogenic mechanism involved in the inflammatory process. Lymphocyte-endothelial interactions mediated by adhesion molecules are important in leukocyte migration and recruitment to sites of inflammation, and selective blockade of these adhesion molecules is a novel and promising strategy to treat Crohn's disease. Therapeutics agents to inhibit leukocyte trafficking include natalizumab (approved for use in Crohn's disease in USA), MLN-02, and ISIS 2302. Other agents being investigated for the treatment of Crohn's disease include inhibitors of T cell activation, proinflammatory cytokine receptors, Th1 polarization, growth hormone, and growth factors. Agents being investigated for treatment of ulcerative colitis include many of those mentioned above. Controlled clinical trials are currently being conducted, exploring the safety and efficacy of old and new biologic agents, and the search certainly will open new and exciting perspective on the development of therapies for inflammatory bowel disease. A review is made of the main areas of research exploring the mechanisms associated with the pathogenesis of IBD, providing advances in the agents currently in use, and identifying a host of new therapeutic biologic targets.
Bosani
Matteo
M
University Hospital, Milan, Italy.
Ardizzone
Sandro
S
Porro
Gabriele Bianchi
GB
Cochrane Database Syst Rev. 2000;(2):CD000067
10796482
Gut. 2000 Jul;47(1):12-4
10861255
J Immunol. 1997 Feb 15;158(4):1582-90
9029093
Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1264-73
11557635
Nature. 1997 Feb 20;385(6618):729-33
9034190
Clin Exp Immunol. 2001 Mar;123(3):347-9
11307797
Eur J Gastroenterol Hepatol. 1996 Oct;8(10):1017-20
8930570
Gut. 2004 Nov;53(11):1646-51
15479686
Aliment Pharmacol Ther. 2003 Jul 15;18(2):175-81
12869077
Gastroenterology. 1995 Jul;109(1):129-35
7797011
J Immunol. 1996 Aug 1;157(3):1261-70
8757634
Gastroenterology. 2002 Sep;123(3):707-13
12198696
Am J Gastroenterol. 2001 Jul;96(7):1977-97
11467623
N Engl J Med. 2000 Jul 13;343(2):108-17
10891520
News Physiol Sci. 2001 Dec;16:272-7
11719604
Eur J Pediatr. 2002 Oct;161 Suppl 1:S88-92
12373579
Lancet. 2002 Jan 5;359(9300):62-9
11809204
Nature. 1997 Feb 20;385(6618):733-6
9034191
Gastroenterology. 2001 Aug;121(2):268-74
11487536
Eur J Immunol. 1997 Oct;27(10):2588-92
9368614
J Immunol. 2000 May 1;164(9):4878-82
10779797
Gastroenterol Clin North Am. 1999 Jun;28(2):297-321
10372270
Gut. 1999 Jun;44(6):812-8
10323882
N Engl J Med. 2007 Jul 19;357(3):239-50
17634459
Gastroenterology. 2001 May;120(6):1347-55
11313304
N Engl J Med. 2007 Jul 19;357(3):228-38
17634458
Nature. 2001 May 31;411(6837):603-6
11385577
Gut. 1997 Mar;40(3):320-7
9135519
Gastroenterology. 2007 Jan;132(1):52-65
17241859
Aliment Pharmacol Ther. 1996 Oct;10(5):721-7
8899079
Immunity. 2001 Jul;15(1):5-14
11485733
Gastroenterology. 2001 May;120(6):1330-8
11313302
Cell. 1995 Dec 15;83(6):835-9
8521507
Aliment Pharmacol Ther. 2001 May;15(5):653-63
11328259
Inflamm Res. 2002 Nov;51(11):522-31
12540016
J Clin Invest. 1996 Dec 1;98(11):2616-22
8958226
N Engl J Med. 1995 Feb 2;332(5):292-7
7816064
Arch Ophthalmol. 1997 Jan;115(1):61-4
9006426
Lancet. 2000 Nov 25;356(9244):1821-2
11117919
Am J Gastroenterol. 2003 Nov;98(11):2372-82
14638336
Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93
16797249
Ann Intern Med. 1995 Jul 15;123(2):132-42
7778826
Lancet. 2002 Jan 26;359(9303):331-40
11830216
J Clin Gastroenterol. 1997 Jul;25(1):330-3
9412914
Gastroenterology. 1997 Aug;113(2):383-9
9247454
Gut. 2002 Jul;51(1):37-43
12077089
Ital J Gastroenterol Hepatol. 1999 May;31(4):313-25
10425578
Gastroenterology. 1999 Jul;117(1):58-64
10381910
Am J Gastroenterol. 2004 Oct;99(10):1984-9
15447761
Gastroenterology. 2001 Aug;121(2):255-60
11487534
Aliment Pharmacol Ther. 2003 Jul 1;18(1):65-75
12848627
Scand J Gastroenterol. 2003;38(5):526-532
28443774
J Immunol. 1999 Jul 15;163(2):1081-90
10395708
Pharmacogenetics. 2002 Oct;12(7):509-15
12360101
Science. 2000 Aug 25;289(5483):1352-5
10958782
Lancet. 2000 Feb 26;355(9205):735-40
10703815
Stem Cells. 1996 Jul;14(4):452-9
8843547
N Engl J Med. 2003 Jan 2;348(1):24-32
12510039
J Immunol. 1996 Oct 15;157(8):3627-34
8871663
Gut. 1991 Sep;32(9):1016-9
1916482
N Engl J Med. 2003 Feb 13;348(7):601-8
12584368
Nature. 2001 May 31;411(6837):599-603
11385576
Blood. 1996 May 1;87(9):3615-24
8611685
Aliment Pharmacol Ther. 2002 Apr;16(4):699-705
11929387
Gastroenterology. 2000 Feb;118(2):264-73
10648454
J Biol Chem. 1997 Jul 25;272(30):18779-89
9228052
Dig Dis Sci. 1996 Aug;41(8):1625-30
8769290
Lancet. 2002 Nov 9;360(9344):1478-80
12433518
Gut. 2009 Mar;58(3):388-95
18824555
Inflamm Bowel Dis. 1997 Summer;3(2):95-113
23282751
Am J Gastroenterol. 2001 Aug;96(8):2373-81
11513177
Gastroenterology. 2000 Dec;119(6):1473-82
11113068
Digestion. 1993;54(4):248-55
8243838
Chest. 1982 Nov;82(5):526-9
6982152
Curr Opin Investig Drugs. 2002 May;3(5):725-34
12090546
Gastroenterology. 1994 Feb;106(2):533-9
8299918
Baillieres Clin Gastroenterol. 1996 Sep;10(3):393-405
8905115
Gastroenterol Clin North Am. 2004 Jun;33(2):191-208, viii
15177534
Br Med J (Clin Res Ed). 1986 Aug 23;293(6545):481
3091168
Eur J Gastroenterol Hepatol. 1999 Jan;11(1):27-32
10495168
Gastroenterology. 2001 May;120(6):1339-46
11313303
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
16472588
Am J Gastroenterol. 2006 Apr;101(4):793-7
16635225
Gastroenterology. 2002 Jul;123(1):106-11
12105838
Lancet. 2001 Jun 16;357(9272):1902-4
11425408
Gastroenterol Clin North Am. 2006 Dec;35(4):757-73
17129812
Aliment Pharmacol Ther. 2003 Jan;17(2):185-92
12534402
Am J Gastroenterol. 1997 Dec;92(12 Suppl):5S-11S
9395346
Gastroenterology. 2000 Oct;119(4):1148-57
11040201
Am J Gastroenterol. 2003 Aug;98(8):1821-6
12907338
J Immunol. 1994 Apr 1;152(7):3530-40
7511650
Aliment Pharmacol Ther. 2003 Aug 1;18(3):263-77
12895211
Inflamm Bowel Dis. 2001 May;7(2):83-8
11383595
Lancet. 2002 May 4;359(9317):1541-9
12047962
Gastroenterology. 1997 Nov;113(5):1465-73
9352848
Dig Dis Sci. 2000 Jun;45(6):1121-9
10877227
N Engl J Med. 2003 Jul 24;349(4):350-7
12878742
Gastroenterology. 2001 May;120(6):1323-9
11313301
Am J Gastroenterol. 2002 Sep;97(9):2357-63
12358256
Gut. 1988 Mar;29(3):352-7
3356367
Cell. 1993 Oct 22;75(2):263-74
8402911
N Engl J Med. 1997 Oct 9;337(15):1029-35
9321530
N Engl J Med. 2000 Jun 1;342(22):1627-32
10833208
J Immunol. 1994 Jun 15;152(12):5883-9
7911491
N Engl J Med. 2004 Nov 11;351(20):2069-79
15537905
Ann Intern Med. 1989 Oct 15;111(8):641-9
2802419
FASEB J. 2000 Sep;14(12):1848-55
10973934
Gastroenterology. 2000 Dec;119(6):1461-72
11113067
N Engl J Med. 2005 Dec 8;353(23):2462-76
16339095
Scand J Gastroenterol. 2002 Jul;37(7):818-24
12190096
Am J Gastroenterol. 2002 Jun;97(6):1458-62
12094865
Aliment Pharmacol Ther. 2003 Oct 1;18(7):741-7
14510748
Gut. 2002 Jul;51(1):5-6
12077079
Gut. 2007 Sep;56(9):1232-9
17299059
Gut. 2004 Sep;53(9):1366-73
15306602
Gastroenterology. 2007 Nov;133(5):1414-22
17920064
Inflamm Bowel Dis. 1999 Feb;5(1):44-60
10028449
Am J Epidemiol. 1987 Mar;125(3):445-52
3812450
Am J Gastroenterol. 2003 Feb;98(2):369-76
12591057
Immunity. 1995 Aug;3(2):171-4
7648390
N Engl J Med. 2004 Feb 26;350(9):876-85
14985485
Am J Gastroenterol. 2001 Mar;96(3):635-43
11280528
Dig Liver Dis. 2003 Nov;35(11):814-7
14674674
Gastroenterology. 1998 Jun;114(6):1133-42
9609749
Gastroenterology. 1999 Mar;116(3):557-65
10029614
Gastroenterology. 2001 Nov;121(5):1088-94
11677200
Gastroenterol Clin North Am. 2002 Mar;31(1):77-92
12122745
Gastroenterology. 2004 Feb;126(2):402-13
14762776
Lancet. 1991 Aug 31;338(8766):570-1
1678821
Gut. 2002 Jul;51(1):30-6
12077088
Rev Gastroenterol Disord. 2003 Spring;3(2):81-92
12776005
Gastroenterology. 1998 Jul;115(1):182-205
9649475
Aliment Pharmacol Ther. 2002 Mar;16(3):399-406
11876692
Gut. 2006 Nov;55(11):1568-74
16603634
Trends Immunol. 2001 May;22(5):244-7
11323280
Gut. 2007 Sep;56(9):1248-56
17317789
Rev Gastroenterol Disord. 2004 Spring;4(2):66-85
15184826
J Biol Chem. 2000 Jun 2;275(22):17051-7
10748117
Science. 1996 Apr 5;272(5258):60-6
8600538
Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59
17355213
N Engl J Med. 2000 Jun 1;342(22):1633-7
10833209
J Immunol. 1999 Jun 1;162(11):6829-35
10352304
J Intern Med. 2002 Dec;252(6):475-96
12472908
Nat Med. 2000 May;6(5):583-8
10802717
Gut. 1998 Jul;43(1):48-55
9771405
Gastroenterology. 1999 Oct;117(4):761-9
10500056
J Exp Med. 1995 Nov 1;182(5):1281-90
7595199